These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 38566153)

  • 1. Super enhancer lncRNAs: a novel hallmark in cancer.
    Song P; Han R; Yang F
    Cell Commun Signal; 2024 Apr; 22(1):207. PubMed ID: 38566153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cis-acting super-enhancer lncRNAs as biomarkers to early-stage breast cancer.
    Ropri AS; DeVaux RS; Eng J; Chittur SV; Herschkowitz JI
    Breast Cancer Res; 2021 Oct; 23(1):101. PubMed ID: 34717732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SELER: a database of super-enhancer-associated lncRNA- directed transcriptional regulation in human cancers.
    Guo ZW; Xie C; Li K; Zhai XM; Cai GX; Yang XX; Wu YS
    Database (Oxford); 2019 Jan; 2019():. PubMed ID: 30806704
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Research progress of super enhancer in cancer].
    Wu ZQ; Mi ZY
    Yi Chuan; 2019 Jan; 41(1):41-51. PubMed ID: 30686784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of super-enhancer-associated functional lncRNAs acting as ceRNAs in ESCC.
    Wang QY; Peng L; Chen Y; Liao LD; Chen JX; Li M; Li YY; Qian FC; Zhang YX; Wang F; Li CQ; Lin DC; Xu LY; Li EM
    Mol Oncol; 2020 Sep; 14(9):2203-2230. PubMed ID: 32460441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Super-enhancers complexes zoom in transcription in cancer.
    Wang M; Chen Q; Wang S; Xie H; Liu J; Huang R; Xiang Y; Jiang Y; Tian D; Bian E
    J Exp Clin Cancer Res; 2023 Jul; 42(1):183. PubMed ID: 37501079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Emerging Role of Super-enhancers as Therapeutic Targets in The Digestive System Tumors.
    Li XP; Qu J; Teng XQ; Zhuang HH; Dai YH; Yang Z; Qu Q
    Int J Biol Sci; 2023; 19(4):1036-1048. PubMed ID: 36923930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Super-lncRNAs: identification of lncRNAs that target super-enhancers via RNA:DNA:DNA triplex formation.
    Soibam B
    RNA; 2017 Nov; 23(11):1729-1742. PubMed ID: 28839111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LncRNA Platr22 promotes super-enhancer activity and stem cell pluripotency.
    Yan P; Lu JY; Niu J; Gao J; Zhang MQ; Yin Y; Shen X
    J Mol Cell Biol; 2021 Aug; 13(4):295-313. PubMed ID: 33049031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Super-enhancers: A new frontier for glioma treatment.
    Cheng M; Zhang ZW; Ji XH; Xu Y; Bian E; Zhao B
    Biochim Biophys Acta Rev Cancer; 2020 Apr; 1873(2):188353. PubMed ID: 32112817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Super enhancers as master gene regulators in the pathogenesis of hematologic malignancies.
    Dębek S; Juszczyński P
    Biochim Biophys Acta Rev Cancer; 2022 Mar; 1877(2):188697. PubMed ID: 35150791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The emerging role of super enhancer-derived noncoding RNAs in human cancer.
    Wang Y; Nie H; He X; Liao Z; Zhou Y; Zhou J; Ou C
    Theranostics; 2020; 10(24):11049-11062. PubMed ID: 33042269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Super-enhancers and novel therapeutic targets in colorectal cancer.
    Liu Q; Guo L; Lou Z; Xiang X; Shao J
    Cell Death Dis; 2022 Mar; 13(3):228. PubMed ID: 35277481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrative analysis of a novel super-enhancer-associated lncRNA prognostic signature and identifying LINC00945 in aggravating glioma progression.
    Yang Z; Zheng Y; Wu H; Xie H; Zhao J; Chen Z; Li L; Yue X; Zhao B; Bian E
    Hum Genomics; 2023 Mar; 17(1):33. PubMed ID: 37004060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncogenic super-enhancer formation in tumorigenesis and its molecular mechanisms.
    Jia Q; Chen S; Tan Y; Li Y; Tang F
    Exp Mol Med; 2020 May; 52(5):713-723. PubMed ID: 32382065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anchoring super-enhancer-driven oncogenic lncRNAs for anti-tumor therapy in hepatocellular carcinoma.
    Yuan XQ; Zhou N; Wang JP; Yang XZ; Wang S; Zhang CY; Li GC; Peng L
    Mol Ther; 2023 Jun; 31(6):1756-1774. PubMed ID: 36461633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting Oncogenic Super Enhancers in MYC-Dependent AML Using a Small Molecule Activator of NR4A Nuclear Receptors.
    Call SG; Duren RP; Panigrahi AK; Nguyen L; Freire PR; Grimm SL; Coarfa C; Conneely OM
    Sci Rep; 2020 Feb; 10(1):2851. PubMed ID: 32071334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The molecular understanding of super-enhancer dysregulation in cancer.
    Yoshino S; Suzuki HI
    Nagoya J Med Sci; 2022 May; 84(2):216-229. PubMed ID: 35967935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LncRNA DSCAM-AS1 interacts with YBX1 to promote cancer progression by forming a positive feedback loop that activates FOXA1 transcription network.
    Zhang Y; Huang YX; Wang DL; Yang B; Yan HY; Lin LH; Li Y; Chen J; Xie LM; Huang YS; Liao JY; Hu KS; He JH; Saw PE; Xu X; Yin D
    Theranostics; 2020; 10(23):10823-10837. PubMed ID: 32929382
    [No Abstract]   [Full Text] [Related]  

  • 20. Oncogenic super-enhancers in cancer: mechanisms and therapeutic targets.
    Bacabac M; Xu W
    Cancer Metastasis Rev; 2023 Jun; 42(2):471-480. PubMed ID: 37059907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.